Taken together, these findings suggest that the activity of the IRX2 protein in breast cancer cells might be associated with the control of chemokine expression and that a loss of IRX2 expression in tumor cells might lead to augmented chemokine secretion, which supports mobilization and increases invasiveness of tumor cells. This evidence concerns the gene IRX2 and breast carcinoma.